Bradley Backes, Ph.D.
Dr. Backes is an Associate Professor at the University of California, San Francisco (UCSF) School of Medicine. He began his career in the pharmaceutical industry, spending nearly 10 years with Novartis and Abbott Laboratories. As the first chemistry hire at the Genomics Institute of the Novartis Research Foundation, he was instrumental in building the organization's chemistry group, protease biology platform and compound screening platform, rising rapidly to the Director level. At Abbott, he contributed to the discovery and invention of several development candidates in the metabolic disease area. Dr. Backes is a co-founder of Pliant Therapeutics and has contributed founding intellectual property to several other biotechnology companies. Dr. Backes earned a Ph.D. from the University of California, Berkeley, and a B.A. in Chemistry from the University of Minnesota.
Dustin Maly, Ph.D.
Dr. Maly is a Raymon E. and Rosellen M. Lawton Distinguished Scholar and Professor of Chemistry at the University of Washington, Seattle. Dr. Maly completed his Ph.D. in Chemistry at the University of California, Berkeley, followed by post-doctoral training at the UCSF, where he was a Susan G. Komen and LSRF Postdoctoral Fellow (Pfizer Fellow). Over the last 8 years, his lab has developed a number of new chemical genetic tools for studying mammalian signaling network and identified unexpected ways in which ATP-competitive kinase inhibitors can affect kinase function. He has received a number of awards including the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Fellowship, and the NSF CAREER Award.
Scott Oakes, M.D.
Dr. Oakes is a Professor of Pathology and member of the Helen Diller Family Comprehensive Cancer Center at UCSF. Dr. Oakes earned his medical degree from the University of Connecticut, Farmington, CT, and completed his residency in anatomic pathology at Brigham and Women's Hospital, Boston. Following residency, he completed a 5-year postdoctoral fellowship in cell biology at Dana-Farber Cancer Center Institute and Harvard Medical School, Boston, MA, where he studied the regulation of the mitochondrial apoptotic pathway. Dr. Oakes was awarded a Howard Hughes Medical Institute Early Career Physician Scientist Award, and is an American Cancer Society Research Scholar, a Harrington Discovery Institute Scholar-Innovator, and an inductee of the American Society of Clinical Investigation.
Feroz Papa, M.D., Ph.D. Dr. Papa is a Professor of Medicine at UCSF. He completed his medical and graduate school training in Biochemistry at the University of Chicago, followed by postgraduate clinical training in internal medicine and endocrinology and a postdoctoral fellowship at UCSF. Dr. Papa is a member of the UCSF Diabetes Center and the California Institute for Quantitative Biosciences (QB3). For over a decade, his lab has been studying the fundamental biology- and small molecule modulation- of the IRE1 life-death switch. He is a recipient of the Charles R. Culpeper Scholar Award, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, and the National Institute of Health Director's New Innovator Award. He has been inducted into the American Society of Clinical Investigation (ASCI), is a Harrington Discovery Institute Scholar-Innovator, and has been elected to the Association of American Physicians (AAP).